Pertinent information included Sample Clauses

Pertinent information included. The notice mentioned in clause a) the nature of the change; b) the date on which the Employer proposes to effect the change; c) the approximate number, type and location of employees likely to be affected by the change; d) the effects the change may be expected to have on the employees' working conditions and terms of employment; e) all other pertinent data relating to the anticipated effects on employees.
View SourceView Similar (15)
Pertinent information included. The notice mentioned in paragraph 35.03 (b) shall be given in writing and shall contain pertinent data including: (a) the nature of the change; (b) the date on which the Corporation proposes to effect the change; (c) the approximate number, type (RSMC or OCRE) and location of employees likely to be affected by the change; (d) the effects the change may be expected to have on the employees’ working conditions and terms of employment; and (e) all other pertinent data relating to the anticipated effects on employees.
View SourceView Similar (5)
Pertinent information included. The notice mentioned in clause 34.03 shall be provided in writing, and shall contain pertinent data including: (a) the nature of the technological change; (b) the date on which the UPCE proposes to effect the technological change; (c) the approximate number, type, and location of employees likely to be affected by the change; (d) the effects that the technological change may be expected to have upon the employee’s working conditions or security of employment; (e) all other pertinent data relating to the anticipated effects on employees.
View SourceView Similar (3)
Pertinent information included. The notice mentioned in clause 22.02 shall be given in writing and shall contain pertinent data including; (a) the nature of the change; (b) the date on which the Company proposes to effect the change; (c) the approximate number of employees likely to be affected by the change.
View SourceView Similar (2)
Pertinent information included. In the discussions referred to in Article 19.06 a) above, the following subject matters may be addressed: i. The nature of the change; ii. The date on which the Company proposes to effect the change; iii. The approximate number, type and location of employees who shall be affected by the change; iv. The effects the change shall have on the employees’ working conditions and terms of employment.
View Source

Related to Pertinent information included

  • OTHER PERTINENT INFORMATION Applicant owns the upland adjoining the lease premises.

  • Client Information Protected Health Information in any form including without limitation, Electronic Protected Health Information or Unsecured Protected Health Information (herein “PHI”);

  • Current Information (a) During the period from the date of this Agreement to the Closing, each Party hereto shall promptly notify each other Party of any (i) significant change in its ordinary course of business, (ii) proceeding (or communications indicating that the same may be contemplated), or the institution or threat or settlement of proceedings, in each case involving the Parties the outcome of which, if adversely determined, could reasonably be expected to have a material adverse effect on the Party, taken as a whole or (iii) event which such Party reasonably believes could be expected to have a material adverse effect on the ability of any party hereto to consummate the Share Exchange. (b) During the period from the date of this Agreement to the Closing, NAS shall promptly notify OTM of any correspondence received from the SEC and FINRA and shall deliver a copy of such correspondence to OTM within one (1) business day of receipt.

  • Patient Information Each Party agrees to abide by all laws, rules, regulations, and orders of all applicable supranational, national, federal, state, provincial, and local governmental entities concerning the confidentiality or protection of patient identifiable information and/or patients’ protected health information, as defined by any other applicable legislation in the course of their performance under this Agreement.

  • Product Information EPIZYME recognizes that by reason of, inter alia, EISAI’s status as an exclusive licensee in the EISAI Territory under this Agreement, EISAI has an interest in EPIZYME’s retention in confidence of certain information of EPIZYME. Accordingly, until the end of all Royalty Term(s) in the EISAI Territory, EPIZYME shall keep confidential, and not publish or otherwise disclose, and not use for any purpose other than to fulfill EPIZYME’s obligations, or exercise EPIZYME’s rights, hereunder any EPIZYME Know-How Controlled by EPIZYME or EPIZYME Collaboration Know-How, in each case that are primarily applicable to EZH2 or EZH2 Compounds (the “Product Information”), except to the extent (a) the Product Information is in the public domain through no fault of EPIZYME, (b) such disclosure or use is expressly permitted under Section 9.3, or (c) such disclosure or use is otherwise expressly permitted by the terms and conditions of this Agreement. For purposes of Section 9.3, each Party shall be deemed to be both the Disclosing Party and the Receiving Party with respect to Product Information. For clarification, the disclosure by EPIZYME to EISAI of Product Information shall not cause such Product Information to cease to be subject to the provisions of this Section 9.2 with respect to the use and disclosure of such Confidential Information by EPIZYME. In the event this Agreement is terminated pursuant to Article 12, this Section 9.2 shall have no continuing force or effect, but the Product Information, to the extent disclosed by EPIZYME to EISAI hereunder, shall continue to be Confidential Information of EPIZYME, subject to the terms of Sections 9.1 and 9.3 for purposes of the surviving provisions of this Agreement. Each Party shall be responsible for compliance by its Affiliates, and its and its Affiliates’ respective officers, directors, employees and agents, with the provisions of Section 9.1 and this Section 9.2.